Market Scenario:
Overactive bladder is
a condition that occurs in various diseases such as Parkinson's disease,
multiple sclerosis, stroke, and others. Rise in prevalence of these diseases
and rapid increase in the global geriatric population are inducing high demand
for effective treatment of overactive bladder, which in turn is propelling the
growth of the global overactive bladder treatment market. Increased marketing
activities, availability of affordable treatments and development of innovative
treatment procedures are also fueling the growth of the global overactive
bladder treatment market. However, low penetration of treatment options in the
healthcare sector and lack of awareness among the population of the
underdeveloped countries are restricting the expansion of the global overactive bladder
treatment market analysis during the assessment period.
The global overactive
bladder treatment market is expected to gain prominence over the forecast
period (2018–2023). It is estimated that the global overactive bladder
treatment market growth is expected to register a CAGR of ~
3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in
developing countries and undesired systemic effects of some current treatment
options may hinder the growth of the market during the assessment period.
Company Profiles
- Astellas Pharma Inc.
- Pfizer, Inc.
- Teva Pharmaceutical
- Allergan, Plc.
- Mylan N.V.
- Endo International Plc
- Hisamitsu Pharmaceutical Co., Inc.
- Sanofi S. A.
- Aurobindo Pharma Limited
- Johnson & Johnson
- Intas Pharmaceuticals Ltd.
- Apotex Inc.
- Macleods Pharmaceuticals Ltd.
- Medtronic PLC
- Cogentix Medical, Inc.
- Others
Segmentation
The global overactive bladder treatment
market is segmented on the basis of pharmacotherapy, non-pharmacological
treatment, and disease.
On the basis of pharmacotherapy, the market
is classified into anticholinergics, Botox, mirabegron, neurostimulation, and
others. Further, anticholinergics are classified into solifenacin, oxybutynin,
fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment
market on the basis of non-pharmacological treatment is segmented into dietary
and fluid modifications, behavioral therapy, pelvic floor muscle
rehabilitation, and others.
On the basis of disease, the market is
segmented into idiopathic overactive bladder and neurogenic overactive bladder.
Further, the neurogenic overactive bladder is segmented into the overactive
bladder in Parkinson’s disease, the overactive bladder in stroke, the
overactive bladder in spinal cord injury, and overactive bladder in other
disorders.
Geographically, the global overactive bladder
treatment market has been segmented into the Americas, Europe, Asia-Pacific,
and the Middle East and Africa. The overactive bladder treatment market in the
Americas is further segmented into North America and South America. North
America is further classified as the US and Canada.
The overactive bladder treatment market in
Europe is segmented into Western Europe and Eastern Europe. Western Europe is
further classified as Germany, France, UK, Italy, Spain, and the rest of
Western Europe.
The overactive bladder treatment market in
Asia-Pacific is segmented into Japan, China, India, Republic of Korea,
Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in
the Middle East and Africa is segmented into the Middle East and Africa.
Regional
Market Summary
The global overactive bladder treatment
market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and
the Middle East and Africa. North America is anticipated to dominate the market
in the Americas owing to the increasing geriatric population, growing
occurrences of OAB, and the availability of numerous healthcare coverage
systems such as Medicare.
Europe is anticipated to hold the second
position in the global overactive bladder treatment market. It is estimated
that the market growth in this region is attributed to the rising incidences of
OAB and availability of reimbursement for certain treatment options. For
instance, the UK’s National Institutes for Health and Care Excellence (NICE)
provides reimbursement for the Botox therapy.
The overactive bladder treatment market in
Asia-Pacific consists of countries, namely, China, Japan, the Republic of
Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region
is expected to be the fastest growing region owing to the growing prevalence of
bladder overactivity, rising geriatric population, rising healthcare
expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold
the least share in the global overactive bladder treatment market. In this
region, the Middle East is expected to dominate owing to the rising healthcare
expenditure and rising occurrences of neurological diseases, especially among
the aged population.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
About US:
Market Research Future
(MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora
Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email:
sales@marketresearchfuture.com
